FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Inavolisib

Drug and asset intelligence for Inavolisib with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Roche →

Mechanism of action

PI3K Inhibitor

Recent signals(2)

ClinicalAugust 4, 2026

Phase I Study of Inavolisib in PIK3CA-Mutant Solid Tumors and Breast Cancer

A Phase I study is evaluating inavolisib's safety and pharmacokinetics in PIK3CA-mutant solid tumors, including breast cancer.

RegulatoryJuly 4, 2026

FDA Accepts Supplement for Inavolisib by Genentech

The FDA has accepted a supplemental NDA for Inavolisib submitted by Genentech.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Inavolisib

July 4, 2026 · N/A

Indications

PIK3CA-mutant Breast Cancer →

Therapeutic areas

Oncology →

Oncology · PI3K Inhibitor →

PI3K Inhibitor →

PIK3CA-mutant Breast Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.